Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15657166 | 0.90 | ACE2 (0.50) | ACE2HSD17B10ANPEPERAP2CXCR4 | |
| SCHEMBL16504257 | 0.88 | ACE2 (0.52) | ACE2CYP2C9CYP2C19SIGMAR1MEN1 | |
| SCHEMBL14980600 | 0.86 | ACE2 (0.63) | ACE2CYP2C9CYP2C19SIGMAR1MEN1 | |
| SCHEMBL16948256 | 0.85 | KDM4E (0.39) | ACE2SMN1; SMN2 | |
| SCHEMBL2478304 | 0.85 | ACE2 (0.47) | ACE2HSD17B10ANPEPERAP2CXCR4 | |
| SCHEMBL19071652 | 0.84 | ACE2 (0.47) | ACE2HSD17B10ANPEPERAP2CXCR4 | |
| SCHEMBL29860788 | 0.84 | ACE2 (0.50) | ACE2HSD17B10ANPEPERAP2CXCR4 | |
| SCHEMBL2478837 | 0.84 | ACE2 (0.59) | ACE2HSD17B10ANPEPERAP2CXCR4 | |
| SCHEMBL13187935 | 0.83 | POLB (0.41) | HSD17B10ANPEPERAP2CXCR4RAD52 | |
| SCHEMBL27077595 | 0.83 | POLB (0.41) | HSD17B10ANPEPERAP2CXCR4RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969353-B2 | Aminoalcohol lipidoids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20110293703-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110293703-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | PHOSPHO1, PNMT, AASDHPPT | ACE2 1076/4885HSD17B10 953/4885ANPEP 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.